AMD to Host Annual Meeting of Stockholders
March 31, 2023 16:29 ET
|
Advanced Micro Devices, Inc.
SANTA CLARA, Calif., March 31, 2023 (GLOBE NEWSWIRE) -- AMD (NASDAQ: AMD) will hold its Annual Meeting of Stockholders on Thursday, May 18, 2023 at 9 a.m. PDT as a virtual meeting accessible at...
Pixium Vision annonce l’obtention du statut Breakthrough Device de la FDA pour le Système Prima dans le traitement de la DMLA sèche
March 31, 2023 01:00 ET
|
Pixium Vision
Pixium Vision annonce l’obtention du statut Breakthrough Device de la FDA pour le Système Prima dans le traitement de la DMLA sèche Pixium Vision et la FDA collaboreront étroitement pendant la phase...
Pixium Vision announces FDA Breakthrough Device Designation for the Prima System in Dry AMD
March 31, 2023 01:00 ET
|
Pixium Vision
Pixium Vision announces FDA Breakthrough Device Designation for the Prima System in Dry AMD Pixium Vision to receive interactive communication with FDA through premarket review phase of Prima System...
Théa Open Innovation and Galimedix announce strategic partnership to develop and commercialize GAL-101, a Phase 2/3-ready small molecule, to treat ophthalmic indications with high unmet medical need
March 29, 2023 08:00 ET
|
Galimedix Therapeutics, Inc.
Galimedix eligible for upfront payment plus various success-based milestone payments and royalties on future net salesEquity investment by Théa Open Innovation into Galimedix supports further...
Réduction du capital social motivée par des pertes par réduction de la valeur nominale: nombre d’actions inchangé
March 17, 2023 02:00 ET
|
Pixium Vision
Réduction du capital social motivée par des pertes par réduction de la valeur nominale : nombre d’actions inchangé Paris, France, 17 mars 2023 – 7 h CET– Le Conseil d’administration de la Société a...
Reduction of share capital due to losses by reduction of nominal value: number of shares unchanged
March 17, 2023 02:00 ET
|
Pixium Vision
Reduction of share capital due to losses by reduction of nominal value: number of shares unchanged Paris, France, March 17, 2023 – 07:00 CET – The Board of Directors of the Company decided at its...
ONL Therapeutics Closes First Tranche of $15 Million Series C Financing to Advance Lead Compound into Phase 2 Clinical Trial
March 08, 2023 07:00 ET
|
ONL Therapeutics
ANN ARBOR, Mich., March 08, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
Anti-Properdin Antibody (NM3086) Demonstrates Efficacy in a Primate Model of Wet-AMD and Dry-AMD
March 06, 2023 08:30 ET
|
Novelmed Therapeutics Inc
---Single therapy for multiple forms of Age-Related Macular Degeneration (AMD) NM3086 is a highly potent Alternative Pathway (AP) blocker that does not affect the Classical Pathway (CP).Dysfunction...
Clinical trials results demonstrate value of home OCT at international meetings
February 22, 2023 08:00 ET
|
Notal Vision
Manassas, VA, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Notal Vision, Inc. reported today that the latest data on its investigational home-based optical coherence tomography (OCT) and how the service can be...
Kinarus Therapeutics Phase 2 KINFAST Covid-19 Clinical Trial Progress Update
February 21, 2023 01:00 ET
|
Kinarus Therapeutic Holding AG
KINFAST is evaluating KIN001 for reduction in severity and duration of Covid-19 symptomsKINFAST is actively enrolling in Germany/Switzerland Basel, Switzerland, 20 February 2023. Kinarus Therapeutics...